Detection of HIV-1 p24 Gag in plasma by a nanoparticle-based bio-barcode-amplification method.

BACKGROUND Detection of HIV-1 in patients is limited by the sensitivity and selectivity of available tests. The nanotechnology-based bio-barcode-amplification method offers an innovative approach to detect specific HIV-1 antigens from diverse HIV-1 subtypes. We evaluated the efficacy of this protein-detection method in detecting HIV-1 in men enrolled in the Chicago component of the Multicenter AIDS Cohort Study (MACS). METHODS The method relies on magnetic microparticles with antibodies that specifically bind the HIV-1 p24 Gag protein and nanoparticles that are encoded with DNA and antibodies that can sandwich the target protein captured by the microparticle-bound antibodies. The aggregate sandwich structures are magnetically separated from solution, and treated to remove the conjugated barcode DNA. The DNA barcodes (hundreds per target) were identified by a nanoparticle-based detection method that does not rely on PCR. RESULTS Of 112 plasma samples from HIV-1-infected subjects, 111 were positive for HIV-1 p24 Gag protein (range: 0.11-71.5 ng/ml of plasma) by the bio-barcode-amplification method. HIV-1 p24 Gag protein was detected in only 23 out of 112 men by the conventional ELISA. A total of 34 uninfected subjects were negative by both tests. Thus, the specificity of the bio-barcode-amplification method was 100% and the sensitivity 99%. The bio-barcode-amplification method detected HIV-1 p24 Gag protein in plasma from all study subjects with less than 200 CD4(+) T cells/microl of plasma (100%) and 19 out of 20 (95%) HIV-1-infected men who had less than 50 copies/ml of plasma of HIV-1 RNA. In a separate group of 60 diverse international isolates, representative of clades A, B, C and D and circulating recombinant forms CRF01_AE and CRF02_AG, the bio-barcode-amplification method identified the presence of virus correctly. CONCLUSIONS The bio-barcode-amplification method was superior to the conventional ELISA assay for the detection of HIV-1 p24 Gag protein in plasma with a breadth of coverage for diverse HIV-1 subtypes. Because the bio-barcode-amplification method does not require enzymatic amplification, this method could be translated into a robust point-of-care test.

[1]  R. Weiss,et al.  Characterization of monoclonal antibodies against the human immunodeficiency virus (HIV) gag products and their use in monitoring HIV isolate variation. , 1987, The Journal of general virology.

[2]  T. Harris,et al.  Catalyzed reporter deposition, a novel method of signal amplification. Application to immunoassays. , 1989, Journal of immunological methods.

[3]  Steven Wolinsky,et al.  Enzymatic amplification of the human immunodeficiency virus in peripheral blood mononuclear cells from pediatric patients. , 1989, The Journal of infectious diseases.

[4]  M N Bobrow,et al.  Catalyzed reporter deposition, a novel method of signal amplification. II. Application to membrane immunoassays. , 1991, Journal of immunological methods.

[5]  C R Cantor,et al.  Immuno-PCR: very sensitive antigen detection by means of specific antibody-DNA conjugates. , 1992, Science.

[6]  E. R. Stiehm,et al.  Rapid serologic testing with immune‐complex‐dissociated HIV p24 antigen for early detection of HIV infection in neonates , 1993, The New England journal of medicine.

[7]  A. Kaplan,et al.  Partial inhibition of the human immunodeficiency virus type 1 protease results in aberrant virus assembly and the formation of noninfectious particles , 1993, Journal of virology.

[8]  G. Satten,et al.  Estimated risk of transmission of the human immunodeficiency virus by screened blood in the United States. , 1995, The New England journal of medicine.

[9]  A. Fauci,et al.  Immunopathogenesis of HIV infection. , 1996, Annual review of microbiology.

[10]  D. Schendel,et al.  Prevalence of selected developmental disabilities in children 3-10 years of age: the Metropolitan Atlanta Developmental Disabilities Surveillance Program, 1991. , 1996, MMWR. CDC surveillance summaries : Morbidity and mortality weekly report. CDC surveillance summaries.

[11]  B. Poiesz,et al.  Comparison of human immunodeficiency virus 1 DNA polymerase chain reaction and qualitative and quantitative RNA polymerase chain reaction in human immunodeficiency virus 1-exposed infants. , 1999, The Pediatric infectious disease journal.

[12]  J. Böni,et al.  Prospective evaluation of amplification-boosted ELISA for heat-denatured p24 antigen for diagnosis and monitoring of pediatric human immunodeficiency virus type 1 infection. , 1999, The Journal of infectious diseases.

[13]  C. A. Macken,et al.  Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. , 1999, The New England journal of medicine.

[14]  D. Ho,et al.  Use of Real-Time PCR and Molecular Beacons To Detect Virus Replication in Human Immunodeficiency Virus Type 1-Infected Individuals on Prolonged Effective Antiretroviral Therapy , 1999, Journal of Virology.

[15]  C. Mirkin,et al.  Scanometric DNA array detection with nanoparticle probes. , 2000, Science.

[16]  P. Vernazza,et al.  Performance of five different assays for the quantification of viral load in persons infected with various subtypes of HIV-1. Swiss HIV Cohort Study. , 2000 .

[17]  J Schüpbach,et al.  Human immunodeficiency virus type 1 p24 concentration measured by boosted ELISA of heat-denatured plasma correlates with decline in CD4 cells, progression to AIDS, and survival: comparison with viral RNA measurement. , 2000, The Journal of infectious diseases.

[18]  J. Rich,et al.  Laboratory testing for infection with the human immunodeficiency virus: established and novel approaches. , 2000, The American journal of medicine.

[19]  P. Vernazza,et al.  Performance of Five Different Assays for the Quantification of Viral Load in Persons Infected With Various Subtypes of HIV‐1 , 2000, Journal of acquired immune deficiency syndromes.

[20]  H. Joller,et al.  Antiretroviral treatment monitoring with an improved HIV‐1 p24 antigen test: an inexpensive alternative to tests for viral RNA , 2001, Journal of medical virology.

[21]  Jaap Goudsmit,et al.  One-Tube Real-Time Isothermal Amplification Assay To Identify and Distinguish Human Immunodeficiency Virus Type 1 Subtypes A, B, and C and Circulating Recombinant Forms AE and AG , 2001, Journal of Clinical Microbiology.

[22]  A. Aldovini,et al.  RNA Incorporation Is Critical for Retroviral Particle Integrity after Cell Membrane Assembly of Gag Complexes , 2002, Journal of Virology.

[23]  Á. Pascual,et al.  Comparison of an Assay Using Signal Amplification of the Heat-Dissociated p24 Antigen with the Roche Monitor Human Immunodeficiency Virus RNA Assay , 2002, Journal of Clinical Microbiology.

[24]  D. Vlahov,et al.  Heat-denatured human immunodeficiency virus type 1 protein 24 antigen: prognostic value in adults with early-stage disease. , 2002, The Journal of infectious diseases.

[25]  Feng Gao,et al.  Diversity Considerations in HIV-1 Vaccine Selection , 2002, Science.

[26]  C. Mirkin,et al.  Nanoparticle-Based Bio-Bar Codes for the Ultrasensitive Detection of Proteins , 2003, Science.

[27]  K. Fransen,et al.  Performance of a quantitative human immunodeficiency virus type 1 p24 antigen assay on various HIV-1 subtypes for the follow-up of human immunodeficiency type 1 seropositive individuals. , 2003, Journal of virological methods.

[28]  B. Clotet,et al.  Lack of Longitudinal Intrapatient Correlation between p24 Antigenemia and Levels of Human Immunodeficiency Virus (HIV) Type 1 RNA in Patients with Chronic HIV Infection during Structured Treatment Interruptions , 2004, Journal of Clinical Microbiology.

[29]  Marc C. Johnson,et al.  The stoichiometry of Gag protein in HIV-1 , 2004, Nature Structural &Molecular Biology.

[30]  H. Günthard,et al.  HIV-1 p24 May Persist During Long-Term Highly Active Antiretroviral Therapy, Increases Little During Short Treatment Breaks, and Its Rebound After Treatment Stop Correlates With CD4+ T Cell Loss , 2005, Journal of acquired immune deficiency syndromes.

[31]  B. Branson,et al.  Evaluation of an Ultrasensitive p24 Antigen Assay as a Potential Alternative to Human Immunodeficiency Virus Type 1 RNA Viral Load Assay in Resource-Limited Settings , 2005, Journal of Clinical Microbiology.

[32]  E. Sanders-Buell,et al.  Biologic and Genetic Characterization of a Panel of 60 Human Immunodeficiency Virus Type 1 Isolates, Representing Clades A, B, C, D, CRF01_AE, and CRF02_AG, for the Development and Assessment of Candidate Vaccines , 2005, Journal of Virology.

[33]  J. Bremer,et al.  Comparison of Two Human Immunodeficiency Virus (HIV) RNA Surrogate Assays to the Standard HIV RNA Assay , 2005, Journal of Clinical Microbiology.

[34]  Kee Suk Ryu,et al.  A modular microfluidic architecture for integrated biochemical analysis. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[35]  Xavier Anglaret,et al.  Transfer and Evaluation of an Automated, Low-Cost Real-Time Reverse Transcription-PCR Test for Diagnosis and Monitoring of Human Immunodeficiency Virus Type 1 Infection in a West African Resource-Limited Setting , 2005, Journal of Clinical Microbiology.

[36]  R. Holzman,et al.  Human Immunodeficiency Virus (HIV) Reverse Transcriptase Activity Correlates with HIV RNA Load: Implications for Resource-Limited Settings , 2005, Journal of Clinical Microbiology.

[37]  Y. P. Bao,et al.  Detection of protein analytes via nanoparticle-based bio bar code technology. , 2006, Analytical chemistry.

[38]  C. Mirkin,et al.  A real-time PCR-based method for determining the surface coverage of thiol-capped oligonucleotides bound onto gold nanoparticles , 2006, Nucleic acids research.

[39]  Chad A Mirkin,et al.  Nanoparticle-Based Biobarcode Amplification Assay (BCA) for Sensitive and Early Detection of Human Immunodeficiency Type 1 Capsid (p24) Antigen , 2007, Journal of acquired immune deficiency syndromes.